Zymeworks ( (ZYME) ) has released its Q4 earnings. Here is a breakdown of the information Zymeworks presented to its investors.
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics to treat challenging diseases, including cancer, inflammation, and autoimmune disorders. The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its product pipeline. Key developments include the initiation of first-in-human studies for ZW191 and ZW171, and the accelerated approval of Ziihera® for HER2-positive biliary tract cancer. Financially, Zymeworks reported a revenue of $76.3 million for 2024, with a net loss of $122.7 million, slightly higher than the previous year. The company has $324.2 million in cash resources, expected to fund operations into the second half of 2027. Looking ahead, Zymeworks plans to continue advancing its pipeline and anticipates further regulatory milestones and strategic partnerships to support its growth and innovation in the biotherapeutics sector.